BMS 754807 – 5 mg

Brand:
Cayman
CAS:
1001350-96-4
Storage:
-20
UN-No:
Non-Hazardous - /

BMS 754807 is a reversible, orally bioavailable dual inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR) tyrosine kinases (IC50s = 1.8 and 1.7 nM, respectively).{28722,28719} It has minimal effect against an array of other tyrosine and serine/threonine kinases.{28722} BMS 754807 inhibits cell proliferation or induces apoptosis in a variety of cancer cells in vitro.{28719} It inhibits the growth of tumor xenografts in mice and this effect is often enhanced by combination therapy with other chemotherapeutics.{28719,28718,28720} Predictive biomarkers, including elevated IGF-1R expression, for effectiveness of BMS 754807 have been delineated.{28721}  

 

Available on backorder

SKU: - Category:

Description

A reversible, orally bioavailable dual inhibitor of IGF-1R and InsR tyrosine kinases (IC50s = 1.8 and 1.7 nM, respectively); inhibits cell proliferation or induces apoptosis in a variety of cancer cells in vitro; inhibits the growth of tumor xenografts in mice


Formal name: 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-N-(6-fluoro-3-pyridinyl)-2-methyl-(2S)-2-pyrrolidinecarboxamide

Synonyms: 

Molecular weight: 461.5

CAS: 1001350-96-4

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|IGF-1R/InsR Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling